Human cancers typically carry several types of genomic variations, such as Single Nucleotide Variants (SNV), Copy Number Variations (CNV), Insertions and Deletions (InDels), Structural Variants (SV), and Gene Fusions. These genetic alterations infer important insights for the discovery and development of biomarkers and for use in basic cancer research, patient stratification and clinical research.
BGI has developed multiple comprehensive and specific cancer panels based on many years of cancer research experience and proprietary database generation. These NGS panels are all capture-based, designed to detect all types of genomic tumor alterations, including base substitutions, insertions and deletions, copy number alterations, and selected gene fusions.
For example, our most comprehensive panel includes 1,053 genes that are strongly supported as clinically actionable cancer genes, with high frequency alterations in the COSMIC database, or play key roles in core cancer pathways.
Solid Tumor Panels
Solid Tumor Panels are available for solid tumor research. All the panels are for Research use only outside of China.
Pan-Cancer panel is designed for the biomarker development and patient enrollment for drug clinical trials in China, including immuno-oncology therapies, targeted therapies, chemo therapies and PARP inhibitors.
The National Medical Products Administration (NMPA) recently approved BGI’s lung cancer panel for in vitro diagnostics (IVD) in China. Hospitals and diagnostic labs in China can use this companion diagnostics panel to detect the EGFR, KRAS and ALK mutation status and allow oncologists to optimally treat Non-Small Cell Lung Cancer (NSCLC) patients who are expected to benefit from multiple approved NSCLC therapies on the market. BGI’s central lab in China also offers an extended version of the panel. Both IVD and the extended versions are part of BGI’s strategy that enables clinical trials for pharmaceutical companies in China.
Solid Tumor Panel Applications
Drug target discovery
Understanding of drug response
Understanding of drug resistance
Under a 21CFR Part 11 compliant LIMS system, your samples are tracked from sample accessioning through data reporting. Highly experienced laboratory professionals follow strict quality procedures to ensure the integrity of the results.
Create a myBGI account to view all our sample and shipping documentation and to manage your project moving forwards. It's quick, free and easy!
Sequencing Service Specification
BGI solid tumor panel sequencing services are executed with the Illumina HiSeq sequencing system, in our CAP and CLIA certified service laboratory in Hong Kong. For samples from China, we offer services from our central laboratories in mainland China, with our NMPA approved MGISEQ-2000 sequencing platform.
Sample Preparation and Services
100bp and 150bp paired-end sequencing options available
NimbleGen SeqCap or KAPA Hyper Prep kit for library construction and enrichment
Raw data and bioinformatics analysis are available in standard file formats
Advanced and custom bioinformatics data analysis available
Cloud-based data storage and delivery system
Sequencing Quality Standard
Guaranteed ≥ 80% of bases with quality score of ≥ Q30
Standard sequencing coverage ≥ 400X is recommended for cancer samples
Turn Around Time
Typical 30 working days from sample QC acceptance to filtered raw data availability for research.
Expedited services are available, including 10-day service for prospective studies. Contact your local BGI specialist for details.
Raw data and bioinformatics analysis are delivered in standard file formats.
Oseq Data Analysis
SNP calling and annotation
SNP validation and comparison
SNP functionality and conservation prediction
InDel calling and annotation
CNV calling and annotation
Gene fusion calling and annotation
We can process your gDNA, Blood, Cell line, Fresh frozen tissue, FFPE samples with the following general requirements: